ID   NTRK3_HUMAN             Reviewed;         839 AA.
AC   Q16288; B7Z4C5; E9PG56; H0YND1; O75682; Q12827; Q16289;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   06-MAR-2007, sequence version 2.
DT   10-MAY-2017, entry version 193.
DE   RecName: Full=NT-3 growth factor receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=GP145-TrkC;
DE            Short=Trk-C;
DE   AltName: Full=Neurotrophic tyrosine kinase receptor type 3;
DE   AltName: Full=TrkC tyrosine kinase;
DE   Flags: Precursor;
GN   Name=NTRK3; Synonyms=TRKC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Fetal brain;
RX   PubMed=7806211; DOI=10.1006/geno.1994.1383;
RA   McGregor L.M., Baylin S.B., Griffin C.A., Hawkins A.L., Nelkin B.D.;
RT   "Molecular cloning of the cDNA for human TrkC (NTRK3), chromosomal
RT   assignment, and evidence for a splice variant.";
RL   Genomics 22:267-272(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), AND PARTIAL PROTEIN
RP   SEQUENCE.
RC   TISSUE=Brain;
RX   PubMed=7823156;
RA   Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P.,
RA   Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.;
RT   "Human trks: molecular cloning, tissue distribution, and expression of
RT   extracellular domain immunoadhesins.";
RL   J. Neurosci. 15:477-491(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9778053; DOI=10.1038/sj.onc.1202100;
RA   Ichaso N., Rodriguez R.E., Martin-Zanca D., Gonzalez-Sarmiento R.;
RT   "Genomic characterization of the human trkC gene.";
RL   Oncogene 17:1871-1875(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   FUNCTION, PHOSPHORYLATION AT TYR-516, INVOLVEMENT IN CHD, VARIANTS
RP   PHE-21; VAL-71; MET-93; ILE-163; PHE-533 AND MET-817, CHARACTERIZATION
RP   OF VARIANTS MET-93; ILE-163; PHE-533 AND MET-817, AND MUTAGENESIS OF
RP   LYS-572.
RX   PubMed=25196463; DOI=10.1002/humu.22688;
RA   Werner P., Paluru P., Simpson A.M., Latney B., Iyer R., Brodeur G.M.,
RA   Goldmuntz E.;
RT   "Mutations in NTRK3 suggest a novel signaling pathway in human
RT   congenital heart disease.";
RL   Hum. Mutat. 35:1459-1468(2014).
RN   [7]
RP   INTERACTION WITH PTPRS.
RX   PubMed=25385546; DOI=10.1038/ncomms6209;
RA   Coles C.H., Mitakidis N., Zhang P., Elegheert J., Lu W., Stoker A.W.,
RA   Nakagawa T., Craig A.M., Jones E.Y., Aricescu A.R.;
RT   "Structural basis for extracellular cis and trans RPTPsigma signal
RT   competition in synaptogenesis.";
RL   Nat. Commun. 5:5209-5209(2014).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 297-401, AND DISULFIDE BOND.
RX   PubMed=10388563; DOI=10.1006/jmbi.1999.2816;
RA   Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M.,
RA   Reilly D., Bass S.H., de Vos A.M.;
RT   "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB
RT   and TrkC.";
RL   J. Mol. Biol. 290:149-159(1999).
RN   [9]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-149; CYS-306; LEU-307; GLN-336;
RP   TYR-677; GLN-678; ARG-768 AND LYS-781.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [10]
RP   VARIANTS SER-664; TYR-677; CYS-736; PRO-745 AND PHE-766.
RX   PubMed=18293376; DOI=10.1002/humu.20707;
RA   Marchetti A., Felicioni L., Pelosi G., Del Grammastro M.,
RA   Fumagalli C., Sciarrotta M., Malatesta S., Chella A., Barassi F.,
RA   Mucilli F., Camplese P., D'Antuono T., Sacco R., Buttitta F.;
RT   "Frequent mutations in the neurotrophic tyrosine receptor kinase gene
RT   family in large cell neuroendocrine carcinoma of the lung.";
RL   Hum. Mutat. 29:609-616(2008).
CC   -!- FUNCTION: Receptor tyrosine kinase involved in nervous system and
CC       probably heart development. Upon binding of its ligand
CC       NTF3/neurotrophin-3, NTRK3 autophosphorylates and activates
CC       different signaling pathways, including the phosphatidylinositol
CC       3-kinase/AKT and the MAPK pathways, that control cell survival and
CC       differentiation. {ECO:0000269|PubMed:25196463}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low
CC       affinity) and dimeric (high affinity) structures (By similarity).
CC       Binds SH2B2. Interacts with SQSTM1 and KIDINS220 (By similarity).
CC       Interacts with PTPRS (PubMed:25385546). {ECO:0000250,
CC       ECO:0000250|UniProtKB:Q03351, ECO:0000269|PubMed:25385546}.
CC   -!- INTERACTION:
CC       Q99523:SORT1; NbExp=2; IntAct=EBI-3936704, EBI-1057058;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=A;
CC         IsoId=Q16288-1; Sequence=Displayed;
CC       Name=2; Synonyms=B;
CC         IsoId=Q16288-2; Sequence=VSP_002925, VSP_002926;
CC       Name=3; Synonyms=C;
CC         IsoId=Q16288-3; Sequence=VSP_002927;
CC       Name=4; Synonyms=D;
CC         IsoId=Q16288-4; Sequence=VSP_002924;
CC       Name=5; Synonyms=E;
CC         IsoId=Q16288-5; Sequence=VSP_002924, VSP_002927;
CC         Note=No experimental confirmation.;
CC   -!- TISSUE SPECIFICITY: Widely expressed but mainly in nervous tissue.
CC       Isoform 2 is expressed at higher levels in adult brain than in
CC       fetal brain.
CC   -!- PTM: Ligand-mediated auto-phosphorylation.
CC   -!- DISEASE: Note=Defects in NTRK3 are associated with susceptibility
CC       to congenital heart defects (CHD). A disease characterized by
CC       congenital developmental abnormalities involving structures of the
CC       heart. CHD are the most common major birth defects and the leading
CC       cause of death from congenital malformations.
CC       {ECO:0000269|PubMed:25196463}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NTRK3ID433.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U05012; AAA75374.1; -; mRNA.
DR   EMBL; S76475; AAB33111.1; -; mRNA.
DR   EMBL; S76476; AAB33112.1; -; mRNA.
DR   EMBL; AJ224521; CAA12029.1; -; Genomic_DNA.
DR   EMBL; AJ224522; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224523; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224524; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224525; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224526; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224527; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224528; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224529; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224530; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224531; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224532; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224533; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224534; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224535; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AK297160; BAH12511.1; -; mRNA.
DR   EMBL; AC009711; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC011966; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC021677; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS10340.1; -. [Q16288-3]
DR   CCDS; CCDS32322.1; -. [Q16288-1]
DR   CCDS; CCDS32323.1; -. [Q16288-2]
DR   CCDS; CCDS58399.1; -. [Q16288-5]
DR   PIR; A55178; A55178.
DR   PIR; I73632; I73632.
DR   PIR; I73633; I73633.
DR   RefSeq; NP_001012338.1; NM_001012338.2. [Q16288-1]
DR   RefSeq; NP_001307063.1; NM_001320134.1.
DR   RefSeq; NP_001307064.1; NM_001320135.1.
DR   RefSeq; NP_002521.2; NM_002530.3.
DR   RefSeq; XP_016877742.1; XM_017022253.1. [Q16288-1]
DR   UniGene; Hs.185701; -.
DR   UniGene; Hs.410969; -.
DR   UniGene; Hs.706364; -.
DR   PDB; 1WWC; X-ray; 1.90 A; A=297-422.
DR   PDB; 3V5Q; X-ray; 2.20 A; A/B=530-832.
DR   PDB; 4YMJ; X-ray; 2.00 A; A/B=530-839.
DR   PDBsum; 1WWC; -.
DR   PDBsum; 3V5Q; -.
DR   PDBsum; 4YMJ; -.
DR   ProteinModelPortal; Q16288; -.
DR   SMR; Q16288; -.
DR   BioGrid; 110971; 39.
DR   DIP; DIP-5723N; -.
DR   IntAct; Q16288; 5.
DR   MINT; MINT-188514; -.
DR   STRING; 9606.ENSP00000354207; -.
DR   BindingDB; Q16288; -.
DR   ChEMBL; CHEMBL5608; -.
DR   GuidetoPHARMACOLOGY; 1819; -.
DR   iPTMnet; Q16288; -.
DR   PhosphoSitePlus; Q16288; -.
DR   BioMuta; NTRK3; -.
DR   DMDM; 134035335; -.
DR   PaxDb; Q16288; -.
DR   PeptideAtlas; Q16288; -.
DR   PRIDE; Q16288; -.
DR   DNASU; 4916; -.
DR   Ensembl; ENST00000317501; ENSP00000318328; ENSG00000140538. [Q16288-2]
DR   Ensembl; ENST00000355254; ENSP00000347397; ENSG00000140538. [Q16288-5]
DR   Ensembl; ENST00000357724; ENSP00000350356; ENSG00000140538. [Q16288-4]
DR   Ensembl; ENST00000360948; ENSP00000354207; ENSG00000140538. [Q16288-1]
DR   Ensembl; ENST00000394480; ENSP00000377990; ENSG00000140538. [Q16288-3]
DR   Ensembl; ENST00000540489; ENSP00000444673; ENSG00000140538. [Q16288-2]
DR   Ensembl; ENST00000557856; ENSP00000453959; ENSG00000140538. [Q16288-5]
DR   Ensembl; ENST00000629765; ENSP00000485864; ENSG00000140538. [Q16288-1]
DR   GeneID; 4916; -.
DR   KEGG; hsa:4916; -.
DR   UCSC; uc059mwc.1; human. [Q16288-1]
DR   CTD; 4916; -.
DR   DisGeNET; 4916; -.
DR   GeneCards; NTRK3; -.
DR   HGNC; HGNC:8033; NTRK3.
DR   HPA; CAB009233; -.
DR   HPA; HPA027484; -.
DR   HPA; HPA048065; -.
DR   MalaCards; NTRK3; -.
DR   MIM; 191316; gene.
DR   neXtProt; NX_Q16288; -.
DR   OpenTargets; ENSG00000140538; -.
DR   Orphanet; 2665; Congenital mesoblastic nephroma.
DR   Orphanet; 2030; Fibrosarcoma.
DR   PharmGKB; PA31819; -.
DR   eggNOG; KOG1026; Eukaryota.
DR   eggNOG; ENOG410YGKQ; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000264255; -.
DR   HOVERGEN; HBG056735; -.
DR   InParanoid; Q16288; -.
DR   KO; K05101; -.
DR   PhylomeDB; Q16288; -.
DR   TreeFam; TF106465; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   SignaLink; Q16288; -.
DR   SIGNOR; Q16288; -.
DR   ChiTaRS; NTRK3; human.
DR   EvolutionaryTrace; Q16288; -.
DR   GeneWiki; TrkC_receptor; -.
DR   GenomeRNAi; 4916; -.
DR   PRO; PR:Q16288; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000140538; -.
DR   CleanEx; HS_NTRK3; -.
DR   ExpressionAtlas; Q16288; baseline and differential.
DR   Genevisible; Q16288; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; IEA:Ensembl.
DR   GO; GO:0043121; F:neurotrophin binding; TAS:ProtInc.
DR   GO; GO:0005030; F:neurotrophin receptor activity; IDA:BHF-UCL.
DR   GO; GO:0002039; F:p53 binding; IPI:BHF-UCL.
DR   GO; GO:0090630; P:activation of GTPase activity; IDA:BHF-UCL.
DR   GO; GO:0000187; P:activation of MAPK activity; IDA:BHF-UCL.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:BHF-UCL.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0090102; P:cochlea development; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IMP:UniProtKB.
DR   GO; GO:0070306; P:lens fiber cell differentiation; IEA:Ensembl.
DR   GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl.
DR   GO; GO:0019056; P:modulation by virus of host transcription; IEA:Ensembl.
DR   GO; GO:0048712; P:negative regulation of astrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0060548; P:negative regulation of cell death; IEA:Ensembl.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0048665; P:neuron fate specification; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IDA:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0048691; P:positive regulation of axon extension involved in regeneration; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0051412; P:response to corticosterone; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR000372; LRRNT.
DR   InterPro; IPR031635; NTRK_C2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR020446; Tyr_kin_neurotrophic_rcpt_3.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR020777; Tyr_kinase_NGF_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF01462; LRRNT; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF16920; TPKR_C2; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01942; NTKRECEPTOR3.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00013; LRRNT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF52058; SSF52058; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS51450; LRR; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Developmental protein; Differentiation; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Immunoglobulin domain; Kinase;
KW   Leucine-rich repeat; Membrane; Neurogenesis; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     31
FT   CHAIN        32    839       NT-3 growth factor receptor.
FT                                /FTId=PRO_0000016731.
FT   TOPO_DOM     32    429       Extracellular. {ECO:0000255}.
FT   TRANSMEM    430    453       Helical. {ECO:0000255}.
FT   TOPO_DOM    454    839       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      104    125       LRR 1.
FT   REPEAT      128    149       LRR 2.
FT   DOMAIN      160    209       LRRCT.
FT   DOMAIN      210    300       Ig-like C2-type 1.
FT   DOMAIN      309    382       Ig-like C2-type 2.
FT   DOMAIN      538    839       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     544    552       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    679    679       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     572    572       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        516    516       Interaction with SHC1. {ECO:0000250}.
FT   SITE        834    834       Interaction with PLC-gamma-1.
FT                                {ECO:0000250}.
FT   MOD_RES     493    493       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6VNS1}.
FT   MOD_RES     516    516       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:25196463}.
FT   MOD_RES     705    705       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     709    709       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     710    710       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     72     72       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     79     79       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    133    133       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    163    163       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    203    203       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    218    218       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    232    232       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    259    259       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    267    267       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    272    272       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    294    294       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    375    375       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    388    388       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     32     38       {ECO:0000250|UniProtKB:Q91044}.
FT   DISULFID     36     45       {ECO:0000250|UniProtKB:Q91044}.
FT   DISULFID    164    189       {ECO:0000250|UniProtKB:Q91044}.
FT   DISULFID    166    207       {ECO:0000250|UniProtKB:Q91044}.
FT   DISULFID    231    284       {ECO:0000250|UniProtKB:Q91044}.
FT   DISULFID    320    362       {ECO:0000244|PDB:1WWC,
FT                                ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:10388563}.
FT   VAR_SEQ     402    410       ESTDNFILF -> V (in isoform 4 and isoform
FT                                5). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_002924.
FT   VAR_SEQ     529    612       YVQHIKRRDIVLKRELGEGAFGKVFLAECYNLSPTKDKMLV
FT                                AVKALKDPTLAARKDFQREAELLTNLQHEHIVKFYGVCGDG
FT                                DP -> WVFSNIDNHGILNLKDNRDHLVPSTHYIYEEPEVQ
FT                                SGEVSYPRSHGFREIMLNPISLPGHSKPLNHGIYVEDVNVY
FT                                FSKGRHGF (in isoform 2).
FT                                {ECO:0000303|PubMed:7823156}.
FT                                /FTId=VSP_002925.
FT   VAR_SEQ     613    839       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:7823156}.
FT                                /FTId=VSP_002926.
FT   VAR_SEQ     712    725       Missing (in isoform 3 and isoform 5).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:7806211,
FT                                ECO:0000303|PubMed:7823156}.
FT                                /FTId=VSP_002927.
FT   VARIANT      21     21       V -> F (rare polymorphism;
FT                                dbSNP:rs200822610).
FT                                {ECO:0000269|PubMed:25196463}.
FT                                /FTId=VAR_074601.
FT   VARIANT      71     71       I -> V (found in patients with CHD;
FT                                unknown pathological significance;
FT                                dbSNP:rs200923715).
FT                                {ECO:0000269|PubMed:25196463}.
FT                                /FTId=VAR_074602.
FT   VARIANT      93     93       T -> M (probable disease-associated
FT                                mutation found in patients with CHD;
FT                                associated with CHD susceptibility;
FT                                significantly reduced
FT                                autophosphorylation; decreased NTRK3
FT                                signaling associated with decreased
FT                                apoptosis in absence of NTF3;
FT                                dbSNP:rs147992979).
FT                                {ECO:0000269|PubMed:25196463}.
FT                                /FTId=VAR_074603.
FT   VARIANT     149    149       T -> R (in a gastric adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs368222977).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041471.
FT   VARIANT     163    163       N -> I (found in patients with CHD;
FT                                unknown pathological significance; no
FT                                change in autophosphorylation; no effect
FT                                on NTRK3 signaling; dbSNP:rs547862658).
FT                                {ECO:0000269|PubMed:25196463}.
FT                                /FTId=VAR_074604.
FT   VARIANT     306    306       R -> C (in dbSNP:rs56386352).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041472.
FT   VARIANT     307    307       V -> L (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041473.
FT   VARIANT     336    336       L -> Q (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041474.
FT   VARIANT     533    533       I -> F (probable disease-associated
FT                                mutation found in patients with CHD;
FT                                associated with CHD susceptibility; no
FT                                change in autophosphorylation; changed
FT                                NTRK3 signaling with decreased apoptosis
FT                                in absence of NTF3; dbSNP:rs869112057).
FT                                {ECO:0000269|PubMed:25196463}.
FT                                /FTId=VAR_074605.
FT   VARIANT     664    664       A -> S (in a lung carcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:18293376}.
FT                                /FTId=VAR_046521.
FT   VARIANT     677    677       H -> Y (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:18293376}.
FT                                /FTId=VAR_041475.
FT   VARIANT     678    678       R -> Q (in dbSNP:rs55890138).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041476.
FT   VARIANT     735    735       R -> F (in a lung large cell carcinoma
FT                                sample; somatic mutation; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_046770.
FT   VARIANT     736    736       W -> C (in a lung carcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:18293376}.
FT                                /FTId=VAR_046522.
FT   VARIANT     745    745       R -> P (in a lung carcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:18293376}.
FT                                /FTId=VAR_046523.
FT   VARIANT     766    766       Y -> F (in a lung carcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:18293376}.
FT                                /FTId=VAR_046524.
FT   VARIANT     768    768       K -> R (in dbSNP:rs55770052).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046771.
FT   VARIANT     781    781       E -> K (in dbSNP:rs56393451).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046772.
FT   VARIANT     817    817       I -> M (probable disease-associated
FT                                mutation found in patients with CHD;
FT                                associated with CHD susceptibility; no
FT                                change in autophosphorylation; changed
FT                                NTRK3 signaling with decreased apoptosis
FT                                in absence of NTF3; dbSNP:rs869209165).
FT                                {ECO:0000269|PubMed:25196463}.
FT                                /FTId=VAR_074606.
FT   MUTAGEN     572    572       K->N: Loss of autophosphorylation and
FT                                loss of NTRK3 signaling.
FT                                {ECO:0000269|PubMed:25196463}.
FT   CONFLICT     65     65       S -> G (in Ref. 4; BAH12511).
FT                                {ECO:0000305}.
FT   CONFLICT     70     70       S -> N (in Ref. 2; AAB33111/AAB33112).
FT                                {ECO:0000305}.
FT   CONFLICT    635    635       D -> N (in Ref. 1; AAA75374).
FT                                {ECO:0000305}.
FT   STRAND      318    326       {ECO:0000244|PDB:1WWC}.
FT   STRAND      332    337       {ECO:0000244|PDB:1WWC}.
FT   STRAND      345    354       {ECO:0000244|PDB:1WWC}.
FT   STRAND      356    367       {ECO:0000244|PDB:1WWC}.
FT   HELIX       370    372       {ECO:0000244|PDB:1WWC}.
FT   STRAND      374    382       {ECO:0000244|PDB:1WWC}.
FT   STRAND      385    393       {ECO:0000244|PDB:1WWC}.
FT   HELIX       535    537       {ECO:0000244|PDB:4YMJ}.
FT   STRAND      538    546       {ECO:0000244|PDB:4YMJ}.
FT   STRAND      548    559       {ECO:0000244|PDB:4YMJ}.
FT   STRAND      562    576       {ECO:0000244|PDB:4YMJ}.
FT   HELIX       579    594       {ECO:0000244|PDB:4YMJ}.
FT   STRAND      603    607       {ECO:0000244|PDB:4YMJ}.
FT   STRAND      610    612       {ECO:0000244|PDB:4YMJ}.
FT   STRAND      614    618       {ECO:0000244|PDB:4YMJ}.
FT   HELIX       625    631       {ECO:0000244|PDB:4YMJ}.
FT   HELIX       653    672       {ECO:0000244|PDB:4YMJ}.
FT   HELIX       682    684       {ECO:0000244|PDB:4YMJ}.
FT   STRAND      685    687       {ECO:0000244|PDB:4YMJ}.
FT   HELIX       689    691       {ECO:0000244|PDB:4YMJ}.
FT   STRAND      693    695       {ECO:0000244|PDB:4YMJ}.
FT   HELIX       706    708       {ECO:0000244|PDB:4YMJ}.
FT   HELIX       734    736       {ECO:0000244|PDB:4YMJ}.
FT   HELIX       739    744       {ECO:0000244|PDB:4YMJ}.
FT   HELIX       749    764       {ECO:0000244|PDB:4YMJ}.
FT   TURN        770    773       {ECO:0000244|PDB:4YMJ}.
FT   HELIX       776    784       {ECO:0000244|PDB:4YMJ}.
FT   HELIX       797    806       {ECO:0000244|PDB:4YMJ}.
FT   HELIX       811    813       {ECO:0000244|PDB:4YMJ}.
FT   HELIX       817    830       {ECO:0000244|PDB:4YMJ}.
SQ   SEQUENCE   839 AA;  94428 MW;  7FE8846830083C08 CRC64;
     MDVSLCPAKC SFWRIFLLGS VWLDYVGSVL ACPANCVCSK TEINCRRPDD GNLFPLLEGQ
     DSGNSNGNAS INITDISRNI TSIHIENWRS LHTLNAVDME LYTGLQKLTI KNSGLRSIQP
     RAFAKNPHLR YINLSSNRLT TLSWQLFQTL SLRELQLEQN FFNCSCDIRW MQLWQEQGEA
     KLNSQNLYCI NADGSQLPLF RMNISQCDLP EISVSHVNLT VREGDNAVIT CNGSGSPLPD
     VDWIVTGLQS INTHQTNLNW TNVHAINLTL VNVTSEDNGF TLTCIAENVV GMSNASVALT
     VYYPPRVVSL EEPELRLEHC IEFVVRGNPP PTLHWLHNGQ PLRESKIIHV EYYQEGEISE
     GCLLFNKPTH YNNGNYTLIA KNPLGTANQT INGHFLKEPF PESTDNFILF DEVSPTPPIT
     VTHKPEEDTF GVSIAVGLAA FACVLLVVLF VMINKYGRRS KFGMKGPVAV ISGEEDSASP
     LHHINHGITT PSSLDAGPDT VVIGMTRIPV IENPQYFRQG HNCHKPDTYV QHIKRRDIVL
     KRELGEGAFG KVFLAECYNL SPTKDKMLVA VKALKDPTLA ARKDFQREAE LLTNLQHEHI
     VKFYGVCGDG DPLIMVFEYM KHGDLNKFLR AHGPDAMILV DGQPRQAKGE LGLSQMLHIA
     SQIASGMVYL ASQHFVHRDL ATRNCLVGAN LLVKIGDFGM SRDVYSTDYY RLFNPSGNDF
     CIWCEVGGHT MLPIRWMPPE SIMYRKFTTE SDVWSFGVIL WEIFTYGKQP WFQLSNTEVI
     ECITQGRVLE RPRVCPKEVY DVMLGCWQRE PQQRLNIKEI YKILHALGKA TPIYLDILG
//
